Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941102 | 1.00 | DPP4 (0.52) | DPP4CASP7G6PDCASP6ALDH1A1 | |
| SCHEMBL9276248 | 0.84 | MAPT (0.39) | DPP4CASP7G6PDCASP6ALDH1A1 | |
| SCHEMBL10316048 | 0.83 | ALDH1A1 (0.49) | DPP4CASP7G6PDCASP6ALDH1A1 | |
| SCHEMBL18980394 | 0.83 | ALDH1A1 (0.48) | DPP4CASP7G6PDCASP6ALDH1A1 | |
| SCHEMBL29860864 | 0.82 | SELL (0.56) | CASP7G6PDCASP6ALDH1A1TSHR | |
| SCHEMBL26963264 | 0.82 | SELL (0.56) | CASP7G6PDCASP6ALDH1A1TSHR | |
| SCHEMBL3667246 | 0.81 | TSHR (0.52) | DPP4CASP7G6PDCASP6ALDH1A1 | |
| SCHEMBL10533170 | 0.80 | SELL (0.60) | DPP4ALDH1A1TSHRCASP1TP53 | |
| SCHEMBL7697637 | 0.78 | SELL (0.64) | CASP7G6PDCASP6ALDH1A1TSHR | |
| SCHEMBL4069345 | 0.78 | DPP4 (0.56) | DPP4ALDH1A1TSHRCASP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007054348-A1 | NOVEL MEDICAMENTS | Ernst-Moritz-Arndt-Universität Greifswald (DE) | 2007-05-18 | — | — | WO | claimed |
| CN-1076439-A | The new derivative of 3-hydroxyanthranilic acid, Preparation Method And The Use | ASTRA AB (SE) | 1993-09-22 | — | — | CN | claimed |
| US-20240122887-A1 | THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | VISTAGEN THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4108239-A1 | THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | Vistagen Therapeutics, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3297619-B1 | THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | VISTAGEN THERAPEUTICS INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11078544-B2 | Method for identifying subjects with aggressive melanoma skin cancer at diagnosis | UNIVERSITEIT MAASTRICHT (NL) | 2021-08-03 | — | — | US | disclosed |
| US-20190321317-A1 | THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | VISTAGEN THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190256926-A1 | METHOD FOR IDENTIFYING SUBJECTS WITH AGGRESSIVE MELANOMA SKIN CANCER AT DIAGNOSIS | MLA DIAGNOSTICS B.V. (NL) | 2019-08-22 | — | — | US | disclosed |
| US-10260109-B2 | Method for identifying subjects with aggressive melanoma skin cancer at diagnosis | UNIVERSITEIT MAASTRICHT (NL) | 2019-04-16 | — | — | US | disclosed |
| EP-3303625-B1 | METHOD FOR IDENTIFYING SUBJECTS WITH AGGRESSIVE MELANOMA SKIN CANCER AT DIAGNOSIS | UNIV MAASTRICHT (NL) | 2019-03-27 | — | — | EP | disclosed |
| US-20180305298-A1 | DEUTERATED CHLOROKYNURENINES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | CEPHALON, INC. | 2018-10-25 | — | — | US | disclosed |
| CN-1121344-A | New compounds | ASTRA AB (SE) | 1996-04-24 | — | — | CN | disclosed |
| EP-0686145-A1 | NEW COMPOUNDS | AKTIEBOLAGET ASTRA (SE) | 1995-12-13 | — | — | EP | disclosed |
| EP-0686144-A1 | NEW COMPOUNDS | Astra Aktiebolag (SE) | 1995-12-13 | — | — | EP | disclosed |
| EP-0643686-A1 | NEW COMPOUNDS | Astra Aktiebolag (SE) | 1995-03-22 | — | — | EP | disclosed |
| WO-1994019316-A1 | NEW COMPOUNDS | AKTIEBOLAGET ASTRA (SE) | 1994-09-01 | — | — | WO | disclosed |
| WO-1994019315-A1 | NEW COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1994-09-01 | — | — | WO | disclosed |
| CN-1076439-A | The new derivative of 3-hydroxyanthranilic acid, Preparation Method And The Use | ASTRA AB (SE) | 1993-09-22 | — | — | CN | disclosed |
| WO-1993005012-A1 | NEW COMPOUNDS | AB ASTRA (SE) | 1993-03-18 | — | — | WO | disclosed |
| EP-0530166-A2 | 3-Hydroxy anthranilic acid derivatives for inhibiting 3-hydroxy anthranilate oxygenase | Astra Aktiebolag (SE) | 1993-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305298-A1 | DEUTERATED CHLOROKYNURENINES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | GRIK3, GRIK1, GRIK2 | DPP4 2644/4885CASP7 4464/4885G6PD 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.